InvestorsHub Logo
Followers 134
Posts 3755
Boards Moderated 0
Alias Born 01/28/2006

Re: Justfactsmam post# 324751

Tuesday, 09/22/2020 8:59:18 PM

Tuesday, September 22, 2020 8:59:18 PM

Post# of 403222
Some posters, do not want to admit how close IPIX is to success. The independent government labs ,both the RBL and PHRI, have demonstrated absolutely undeniable in vitro results of Brilacidin against the sars-cov-19 virus.

Most Covid19 in vitro research as well as human trials have been funded by their big pharmaceutical companies trying to resurrect antiviral drugs which have under performed or even failed for other indications. The Big pharmas have manipulated trials in progress to make their drugs results appear better than they actually are.

Brilacidin is only a few weeks away from human trials. The pre trial price run up could start at any time. Between now and the start of human trials.We are should to have the following announcements:

- Pre IND meeting
- Pre print peer review articles
- CRO contract
- IND approval
- CDMO contract
- Human trial location[s]
- Trial protocol
-
Then the trials themselves will be short as are all infectious disease trials. Brilacidin may show results soon after the first infusion. Testing will determine the reduction of the viral load, reduction of systemic symptoms, reduced viral shedding and soon reduction in complications and mortality. A trend in the testing may be reported in an interim report.

Below is an article regarding the measurements done when the antiviral, Tamiflu, is given for influenza and the testing to measure drug response to the virus. Brilacidin will have similar tests performed

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110250/

IMO only ...time is getting short to accumulate shares at these prices. Of course human clinical trials can be unpredictable, but Brilacidin's pre trial results should give IPIX of a chance at success.

GLTA,Farrell




Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News